Accessibility Menu
China Pharma logo

China Pharma(NYSEMKT) CPHI

Market Cap$38.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-100%
5 Year-100%
1 Year-36%
1 Month-20%
$0.89
-2.06%
-0.02Today
China Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.892026-08-31
China Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.79%USD 0.952026-08-24
1 month-20.23%USD 1.112026-07-31
3 month+3%USD 0.862026-06-02
Year to date-26.82%USD 1.212025-12-31
1 year-36.29%USD 1.392025-08-29
3 year-89.51%USD 8.442023-09-01
5 year-99.74%USD 343.502021-09-01
Since inception-99.88%USD 750.002002-04-17

China Pharma Financials at a Glance

Market Cap

$38.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.91M

Net Income (TTM)

-$4.47M

EPS (TTM)

-$0.42

P/E Ratio

-2.13

Dividend

$0.00

Beta (Volatility)

1.01 (Average)

Price

$0.89

Volume

406,081.96

Open

$0.92

Previous Close

$0.89

Daily Range

$0.87 - $0.96

52-Week Range

$0.38 - $19.19

Estimated Earnings Date

May 15, 2026

CPHI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About China Pharma

China Pharma makes medicines for hospitals and pharmacies in China. Its products help treat infections, heart disease, and digestive problems. These medicines support patients with common health issues like high blood pressure or infections.

Pills, Powders, and More: What’s on Offer?

  • Anti-Viral/Infection & Respiratory (60%): Tablets and capsules for infections and respiratory illnesses, used by hospitals and clinics.
  • CNS/Cerebral-Cardiovascular (32%): Injections and pills for brain and heart conditions, targeting patients with memory loss or heart disease.
  • Digestive Diseases (6%): Medicines for liver and stomach problems, supporting patients with digestive disorders.
  • Other Healthcare (2%): Vitamin injections, anti-nausea drugs, food supplements, masks, and sanitizers for general health and protection.

Growth Spurts and Strategic Moves

  • Expanded into protective products like masks and sanitizers in 2020-2021.
  • Launched contract manufacturing (CMO) services in 2024, registering with Chinese regulators in 2025.
  • Acquired patents for new drug formulations in 2024-2025, including diabetes and heart medications.
  • Shifted focus to generic drug consistency evaluation in 2023 to meet procurement rules.

What Makes China Pharma Stand Out?

The company sells only in China, using a network of distributors and sales offices. Its product range covers both generic and branded drugs, with a focus on high-need diseases. Two production sites in Hainan Province support a flexible manufacturing approach.

Five Things You Need to Know

  • Revenue was $4.1 million in FY2025, down 8.5% from FY2024.
  • Anti-viral and infection drugs made up 60% of FY2025 sales.
  • Gross loss margin improved to -3.2% in FY2025 from -43.8% in FY2024.
  • Operating loss was $3.24 million in FY2025, down from $4.59 million in FY2024.
  • Cash and cash equivalents were $0.35 million as of December 31, 2025.

Bottom Line

China Pharma has shifted its product mix and expanded into new health categories. The company faces ongoing financial and regulatory challenges but continues to adapt its business model.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

221

CEO

Zhi Lin Li

Website

www.chinapharmaholdings.com

Headquarters

Haikou, HA 570216, CN

CPHI Financials

Key Financial Metrics (TTM)

Gross Margin

-9.33%

Operating Margin

-111.84%

Net Income Margin

-114.33%

Return on Equity

-17.14%

Return on Capital

-11.60%

Return on Assets

-10.01%

Earnings Yield

-46.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$38.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

43.02M

Volume

406.08K

Avg. Volume

4.38M

Financials (TTM)

Gross Profit

-$365.11K

Operating Income

-$4.38M

EBITDA

-$1.44M

Operating Cash Flow

-$173.12K

Capital Expenditure

-$6.38K

Free Cash Flow

-$179.50K

Cash & ST Invst.

$304.87K

Total Debt

$3.75M

China Pharma Performance Analysis

China Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,104,092-15.9%
20232023-12-31USD 7,011,299-13.5%
20242024-12-31USD 4,528,929-35.4%
20252025-12-31USD 4,144,268-8.5%
China Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-26.3%
Q42025-12-3162.1%
Q12026-03-31-19.8%
Q22026-06-30-3.6%
China Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -37.792.6%
20232023-12-31USD -9.10-75.9%
20242024-12-31USD -2.71-70.2%
20252025-12-31USD -0.74-72.6%
China Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.3%
Q42025-12-31-35.3%
Q12026-03-31-17.4%
Q22026-06-30-25.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$948.34K

-7.5%

Gross Profit

$83.57K

+196.0%

Gross Margin

8.81%

N/A

Market Cap

$38.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$180.91K

N/A

Employees

215

N/A

Net Income

-$1.46M

-176.0%

EBITDA

-$329.91K

-83.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$304.87K

-51.2%

Total Debt

$3.75M

+9.5%

Accounts Receivable

$248.25K

-21.7%

Inventory

$1.36M

-18.8%

Long Term Debt

$75.29K

-94.3%

Short Term Debt

$3.68M

+74.6%

Return on Assets

-10.01%

N/A

Return on Invested Capital

-11.82%

N/A

Free Cash Flow

-$32.83K

-111.7%

Operating Cash Flow

-$32.83K

-111.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KALAKALA BIO, Inc.
$0.67-2.52%
XBIOXenetic Biosciences, Inc.
$4.19+5.28%
ENSCEnsysce Biosciences, Inc.
$0.39-1.80%
SNGXSoligenix, Inc.
$0.38+0.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About CPHI

What is the current price of China Pharma?

China Pharma is trading at $0.89 per share.

What is the 52-week range for China Pharma?

Over the past 52 weeks, China Pharma has traded between $0.38 and $19.19.

How much debt does China Pharma have?

As of the most recent reporting period, China Pharma reported total debt of $3.91M.

How much cash does China Pharma have on hand?

China Pharma reported $304.87K in cash and cash equivalents in its most recent financial results.

What is China Pharma’s dividend yield?

China Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services